High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 11, 2012, Pages 1291-1298

  Tandon, Puneeta ^a,b   DeLisle, Angela ^c   Topal, Jeffrey E ^b   Garcia Tsao, Guadalupe ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Bacteriology; Epidemiology; Multidrug resistance; SBP

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; RIFAXIMIN; TICARCILLIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PERITONITIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84867676924     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.08.017     Document Type: Article

References (46)

1. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28:26-42.
2. Fernández J., Navasa M., Gómez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
3. Fernández J., Acevedo J., Castro M., et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012, 55:1551-1561.
4. Ariza X., Castellote J., Lora-Tamayo J., et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012, 56:825-832.
5. Novovic S., Semb S., Olsen H., et al. First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage. Scand J Gastroenterol 2012, 47:212-216.
6. Umgelter A., Reindl W., Miedaner M., et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009, 37:2-8.
7. Baquero F. Antibiotic resistance in Spain: what can be done?. Task Force of the General Direction for Health planning of the Spanish Ministry of Health. Clin Infect Dis 1996, 23:819-823.
8. Turner P.J. Extended-spectrum beta-lactamases. Clin Infect Dis 2005, 41(Suppl 4):S273-S275.
9. Albrich W.C., Monnet D.L., Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004, 10:514-517.
10. Levy S.B., O'Brien T.F. Global antimicrobial resistance alerts and implications. Clin Infect Dis 2005, 41(Suppl 4):S219-S220. Alliance for the Prudent Use of Antibiotics.
11. Levy S.B. Antibiotic resistance worldwide-a Spanish task force responds. Clin Infect Dis 1996, 23:824-826.
12. Amin P.B., Magnotti L.J., Fischer P.E., et al. Prophylactic antibiotic days as a predictor of sensitivity patterns in Acinetobacter pneumonia. Surg Infect (Larchmt) 2011, 12:33-38.
13. Scarpignato C., Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005, 51(Suppl 1):36-66.
14. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55:1619-1629.
15. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
16. Gustot T., Durand F., Lebrec D., et al. Severe sepsis in cirrhosis. Hepatology 2009, 50:2022-2033.
17. Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010, 139:1246-1256.
18. Siegel J.D., Rhinehart E., Jackson M., et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007, 35(Suppl 2):S165-S193.
19. Angeloni S., Leboffe C., Parente A., et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008, 14:2757-2762.
20. Park Y.H., Lee H.C., Song H.G., et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003, 18:927-933.
21. Cheong H.S., Kang C.I., Lee J.A., et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009, 48:1230-1236.
22. Singh N., Wagener M.M., Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003, 9:531-537.
23. Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010, 8:979-985.
24. Acevedo J., Fernandez J., Castro M., et al. Current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection (abstr). J Hepatol 2009, 50:S5.
25. Drinka P., Niederman M.S., El-Solh A.A., et al. Assessment of risk factors for multi-drug resistant organisms to guide empiric antibiotic selection in long term care: a dilemma. J Am Med Dir Assoc 2011, 12:321-325.
26. Chon Y.E., Kim S.U., Lee C.K., et al. Community-acquired versus nosocomial spontaneous bacterial peritonitis in patients with liver cirrhosis. J Hepatol 2011, 54(Suppl 1):S379.
27. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002, 136:834-844.
28. Shorr A.F., Zilberberg M.D., Micek S.T., et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008, 168:2205-2210.
29. Wright G.D. Q&A: antibiotic resistance: where does it come from and what can we do about it?. BMC Biol 2010, 8:123.
30. Wu U.I., Yang C.S., Chen W.C., et al. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 2010, 43:310-316.
31. Caffrey A.R., Quilliam B.J., LaPlante K.L. Risk factors associated with mupirocin resistance in methicillin-resistant Staphylococcus aureus. J Hosp Infect 2010, 76:206-210.
32. Yan J.J., Ko W.C., Wu J.J., et al. Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 2004, 42:3329-3332.
33. Du B., Long Y., Liu H., et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002, 28:1718-1723.
34. Rodríguez-Baño J., Navarro M.D., Romero L., et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004, 42:1089-1094.
35. Wright G.D. Molecular mechanisms of antibiotic resistance. Chem Commun (Camb) 2011, 47:4055-4061.
36. Fraimow H.S., Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011, 27:163-205.
37. Llovet J.M., Rodríguez-Iglesias P., Moitinho E., et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997, 26:88-95.
38. Mas A., Rodes J., Sunyer L., et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003, 38:51-58.
39. Jiang Q., Jiang X.H., Zheng M.H., et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008, 20:1064-1070.
40. Maclayton D.O., Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009, 43:77-84.
41. Adachi J.A., DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006, 42:541-547.
42. Debbia E.A., Maioli E., Roveta S., et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008, 20:186-194.
43. DuPont H.L. Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother 2011, 12:293-302.
44. DuPont H.L., Jiang Z.D. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 2004, 10:1009-1011.
45. Ruiz J., Mensa L., Pons M.J., et al. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008, 61:1016-1019.
46. Concepcion M., Poca M., Gordillo J., et al. Evolution of antibiotic susceptibility of bacteria causing spontaneous bacterial peritonitis: a 9-year study. J Hepatol 2011, 54(Suppl 1):S380.